A Study to Evaluate the Process of Aging in Human Atherosclerosis

Overview

About this study

The purpose of this study is to critically test the hypothesis that senescent-cell derived factors (cell aging), in particular IGFBP3, suppress the innate repair capacity of vascular smooth muscle cells (VSMC) in human atherosclerosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Subject must be > 18 years of age.
Subjects will be undergoing routine endarterectomy to remove culprit atheromas in either the carotid, aortoiliac, or femoral arterial beds.
All eligible subjects regardless of race or gender or ethnicity will be eligible and included in the study.

Exclusion Criteria:

None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Fahad Shuja, M.B.B.S.	Open for enrollment	Contact information: Fahad Shuja M.B.B.S. (507)284-1575 Shuja.Fahad@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fahad Shuja, M.B.B.S.

Open for enrollment

Contact information:

Fahad Shuja M.B.B.S.

(507)284-1575

Shuja.Fahad@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials